Future work should prioritize prospective multicenter registries with standardized datasets and routine molecular/immune (CTNNB1/APC, PD-1/PD-L1) profiling, correlating biomarkers with growth, recurrence, and response to watch-and-wait, surgery, or systemic therapy to refine risk stratification and individualize care as happening for endometrial and ovarian cancer. This evidence concerns the gene APC and ovarian carcinoma.